1. MARKETS
  2. SECTOR : HEALTHCARE
  3. INDUSTRY : HEALTHCARE FACILITIES
  4. GUJARAT KIDNEY AND SUPER SPECIALITY LTD.
Gujarat Kidney and Super Speciality Ltd.
NSE: GKSL | BSE: 544666

Gujarat Kidney and Super Live Share Price Today, Share Analysis and Chart

aboutGujarat Kidney and Super Speciality Ltd. (GKSL) is a healthcare provider based in Vadodara, Gujarat, specializing in nephrology, urology, and other super-speciality medical services. The company operates a dedicated hospital facility that focuses on ... Read More
Ask AI about Gujarat Kidney and Super
149.28-1.27(-0.84%)
731.6K
NSE+BSE Volume

NSE 20 Nov, 2026 3:31 PM

Portfolio

Alert

My Notes

Gujarat Kidney and Super Stock Price Ranges

Day Price Range

-0.8% 1 Day return
149.3 (LTP)
147.3155.2
LowHigh

Week Price Range

-4.1% 1 Week return
149.3 (LTP)
147.3163.4
LowHigh

Month Price Range

-20.5% 1 Month return
149.3 (LTP)
147.3193
LowHigh

52 Week Price Range

31.0% 1 Year return
149.3 (LTP)
98.4209.8
LowHigh

Gujarat Kidney and Super Technical Analysis

Gujarat Kidney and Super EMA & SMA

Bearish-6
Bullish1
Bearish7
5 Day152.6
10 Day155.4
12 Day156.5
20 Day160.5
26 Day162.7
50 Day164.6
100 Day157.4
200 Day137.3

Gujarat Kidney and Super Delivery And Volume

Daily Avg. Delivery Volume %
20 Nov, 202646.9%
Week52.2%
Month52.1%
PositiveNeutralNegative

Gujarat Kidney and Super Resistance and Support

150.60
Pivot
First Resistance153.9
Second Resistance158.5
Third Resistance161.7
First Support146.0
Second Support142.8
Third Support138.2
Day RSI31.4
Day MACD-6.2
Day MFI16.4
Day MACD Signal Line-5.5

Gujarat Kidney and Super Beta

1 Month0.5
1 Year-
3 Month0.1
3 Year-

Gujarat Kidney and Super Price Change Analysis

↓-20.5%
Over 1 Month
LowHigh
147.3193.0
↓-4.6%
Over 3 Months
LowHigh
147.3209.8
↑6.3%
Over 6 Months
LowHigh
122.2209.8
↑31.0%
Over 1 Year
LowHigh
98.4209.8

Gujarat Kidney and Super Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Pragnesh Yashwantsinh BharpodaPromoter30,084,25038.2 %
Goldman Sachs Investments (Mauritius) I LtdFii2,760,0003.5 %
Ashika Global Finance Private LimitedPublic1,000,0001.3 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Gujarat Kidney and Super Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
NEXUS GLOBAL OPPORTUNITIES FUNDBulkSell26 Oct 2026178438,656NSE
NATVARSINH T CHAVDABulkSell07 Oct 2026192.19486,148NSE
NATVARSINH T CHAVDABulkPurchase07 Oct 2026188.97471,148NSE
NATVARSINH T CHAVDABulkSell05 Oct 2026192.11721,367NSE
QE SECURITIES LLPBulkSell05 Oct 2026190.48427,062NSE
QE SECURITIES LLPBulkPurchase05 Oct 2026192.61443,342NSE
NATVARSINH T CHAVDABulkPurchase05 Oct 2026189.10721,367NSE
PRIYAL BOHRABulkSell01 Oct 2026193.41399,546NSE
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkSell01 Oct 2026199.931,030,937NSE
GRT STRATEGIC VENTURES LLPBulkSell01 Oct 2026198.93570,047NSE

Gujarat Kidney and Super Corporate Actions

Gujarat Kidney and Super Board Meetings

Gujarat Kidney and Super past and upcoming board meetings.

#Ex-Date
PurposeNotes
104 Nov 2026
Quarterly Results-
214 Aug 2026
Quarterly Results-
328 May 2026
Audited Results-
414 Feb 2026
Quarterly Results(Revised)

Gujarat Kidney and Super Research Reports

Gujarat Kidney and Super research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
121 Dec 2025Hem Securities--IPO Subscribe--%pdf
218 Dec 2025Ventura--IPO Note--%pdf

Gujarat Kidney and Super Corporate Filings

Gujarat Kidney and Super BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
11 Nov 2026
Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earning Call conducted on 05/11/2026
PDF
05 Nov 2026
Q2FY27 Quarterly Result Announced for Gujarat Kidney and Super Speciality Ltd.
Healthcare Facilities company Gujarat Kidney and Super Speciality announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations: For Q2FY27, revenue from operations stood at Rs 3,809.02 lakh, reflecting a QoQ increase of 11.08% compared to Rs 3,428.92 lakh in Q1FY27 and a YoY expansion of 194.61% from Rs 1,292.88 lakh in Q2FY26. For H1FY27, it reached Rs 7,237.94 lakh, up by 156.76% YoY relative to Rs 2,818.90 lakh in H1FY26. Total income: For Q2FY27, total income achieved Rs 3,867.69 lakh, showcasing an 10.57% QoQ growth over Rs 3,497.82 lakh in Q1FY27 and a 197.13% YoY growth against Rs 1,301.67 lakh in Q2FY26. For H1FY27, total income stood at Rs 7,365.51 lakh, marking a YoY growth of 160.40% against Rs 2,828.52 lakh in H1FY26. Profit before tax (PBT): For Q2FY27, PBT arrived at Rs 862.49 lakh, higher by 23.86% QoQ from Rs 696.35 lakh in Q1FY27 and up by 113.99% YoY over Rs 403.06 lakh in Q2FY26. For H1FY27, PBT grew 35.32% YoY to Rs 1,558.84 lakh relative to Rs 1,151.97 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, PAT stood at Rs 659.80 lakh, an expansion of 24.00% QoQ over Rs 532.10 lakh in Q1FY27 and an increase of 129.38% YoY compared to Rs 287.64 lakh in Q2FY26. For H1FY27, PAT rose by 43.96% YoY to Rs 1,191.90 lakh from Rs 827.96 lakh in H1FY26. Earnings per share (EPS): For Q2FY27, basic and diluted EPS stood at Rs 0.74, increasing by 12.12% QoQ against Rs 0.66 in Q1FY27 and up by 42.31% YoY from Rs 0.52 in Q2FY26. For H1FY27, basic and diluted EPS arrived at Rs 1.40, lower by 4.76% YoY relative to Rs 1.47 in H1FY26. Standalone Financial Highlights: Revenue from operations: For Q2FY27, standalone revenue from operations was reported at Rs 803.56 lakh, showing a QoQ drop of 13.06% against Rs 924.27 lakh in Q1FY27 and a YoY drop of 16.67% from Rs 964.26 lakh in Q2FY26. For H1FY27, revenue from operations declined by 18.09% YoY to Rs 1,727.83 lakh versus Rs 2,109.25 lakh in H1FY26. Total income: For Q2FY27, total income stood at Rs 855.66 lakh, down by 13.46% QoQ from Rs 988.79 lakh in Q1FY27 and lower by 11.40% YoY from Rs 965.77 lakh in Q2FY26. For H1FY27, total income came in at Rs 1,844.45 lakh, down by 12.62% YoY relative to Rs 2,110.91 lakh in H1FY26. Profit before tax (PBT): For Q2FY27, PBT stood at Rs 211.88 lakh, reducing by 20.11% QoQ relative to Rs 265.22 lakh in Q1FY27 and falling by 32.18% YoY against Rs 312.44 lakh in Q2FY26. For H1FY27, PBT fell by 44.04% YoY to Rs 477.10 lakh from Rs 852.69 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, PAT arrived at Rs 177.64 lakh, dropping 12.80% QoQ over Rs 203.71 lakh in Q1FY27 and down 22.81% YoY compared to Rs 230.12 lakh in Q2FY26. For H1FY27, PAT decreased by 38.50% YoY to Rs 381.35 lakh against Rs 620.10 lakh in H1FY26. Earnings per share (EPS): For Q2FY27, basic and diluted EPS came in at Rs 0.23, down by 11.54% QoQ against Rs 0.26 in Q1FY27 and lower by 48.89% YoY from Rs 0.45 in Q2FY26. For H1FY27, basic and diluted EPS reached Rs 0.48, down by 60.66% YoY against Rs 1.22 in H1FY26. Result PDF
PDF
05 Nov 2026
Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication for Unaudited Financial Statements for the Quarter ended September 2026.
PDF
05 Nov 2026
Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of earning call
PDF
05 Nov 2026
Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Investor Presentation
Revised presentation Uploaded for today''s Earning Con-Call.
PDF

Gujarat Kidney and Super Documents

Gujarat Kidney and Super Earnings Call

Gujarat Kidney and Super earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
11 Nov 2026Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
05 Nov 2026Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Gujarat Kidney and Super Annual Reports

Gujarat Kidney and Super financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026
2026Annual Report Mar-2026

Gujarat Kidney and Super Investor Presentations

Gujarat Kidney and Super investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
05 Nov 2026Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Investor Presentation
04 Nov 2026Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Investor Presentation

Gujarat Kidney and Super - Company Profile

Gujarat Kidney and Super Management Structure

Gujarat Kidney and Super management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Bhartiben Pragnesh BharpodaExecutive Director,Whole Time Director,Chief Operating Officer18Mar 26
Mrs Bhavika PatelChief Financial Officer-Mar 26
Vishakha Mahesh PhadkeCompany Secretary,Compliance Officer-Mar 26

Gujarat Kidney and Super Board of Directors

Gujarat Kidney and Super Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Pragnesh BharpodaED / MD / Promoter18Mar 26
Bharti Pragnesh BharpodaExecutive Director / WTD / Chief Operating Officer18Mar 26
Jagdish Vinodchandra ThakkarIndependent Non Exe. Director0.85Mar 26
Anita BharpodaNon Executive Director-Mar 26
Udayan Maheshkant KachchhiIndependent Non Exe. Director-Mar 26
Kairavi Naimesh ShahIndependent Non Exe. Director-Mar 26
Paresh DhotiIndependent Non Exe. Director-Mar 26
Disha BharpodaIndependent Non Exe. Director-Mar 26
Vishakha Mahesh PhadkeCompany Sec. & Compli. Officer-Mar 26

About the company - Business Profile

Gujarat Kidney and Super Speciality Ltd. (GKSL) is a healthcare provider based in Vadodara, Gujarat, specializing in nephrology, urology, and other super-speciality medical services. The company operates a dedicated hospital facility that focuses on comprehensive kidney care, including diagnostics, surgical interventions, and long-term management of renal conditions. GKSL serves the regional market in Gujarat, positioning itself as a specialized center for high-end medical care in its core domains.

Key Points

  • Key Facts:
    • Founded Year: Incorporated in 2019 (CIN: U85300GJ2019PLC111559).
    • Headquarters: Vadodara, Gujarat.
    • Stock Listing: Listed on the Bombay Stock Exchange (BSE) [Stock Code: GKSL].
  • Operations and Facilities: The company operates from its facility located at Plot No. 1, Jetalpur Road, Alkapuri, Vadodara. The hospital provides specialized medical services including dialysis, kidney transplants, and urological surgeries.
  • Revenue Breakdown:
    • For the financial year ended March 31, 2025, the company reported a total comprehensive income of ₹921.13 Lakhs on a standalone basis and ₹980.86 Lakhs on a consolidated basis.
    • For the nine months ended December 31, 2025, consolidated profit after tax (PAT) reached ₹1,198.59 Lakhs, showing significant growth compared to the previous year's figures.
    • Revenue is primarily generated from healthcare services, including inpatient and outpatient treatments within the Gujarat region.
  • Key Products and Services:
    • Nephrology: Management of acute and chronic kidney diseases, including specialized dialysis services.
    • Urology: Surgical and medical treatments for urinary tract conditions.
    • Super Speciality Care: Advanced diagnostic and therapeutic services for complex medical cases requiring specialized expertise.
  • Strategic Initiatives and Outlook:
    • The company is focused on expanding its service offerings within the super-speciality segment to capture a larger share of the tertiary healthcare market in Gujarat.
    • Recent financial performance indicates a focus on scaling operations, with consolidated profits for the nine-month period ending December 2025 already exceeding the full-year figures for FY 2024-25.
  • Financial Performance Summary:
    • Earnings Per Share (EPS): For the year ended March 31, 2025, the basic and diluted EPS stood at ₹1.79 (standalone) and ₹1.85 (consolidated).
    • Growth Trend: Net profit for the period ending December 31, 2025, showed a substantial increase, reaching ₹1,045.51 Lakhs for the owners of the company compared to ₹813.56 Lakhs in the corresponding period of the previous year.

References

  1. Result Mar 2026
  2. Result Feb 2026

Gujarat Kidney and Super FAQ

Gujarat Kidney and Super today is trading in the red, down by 0.84% at ₹149.28.
Gujarat Kidney and Super is currently trading down 0.84% on an intraday basis. In the past week the stock fell 4.12%. Stock has been down 4.56% in the past quarter and rose 30.95% in the past year. You can view this in the share price history/seasonality section.
Gujarat Kidney and Super is listed on NSE with the ticker GKSL and on BSE as 544666. It's currently trading on NSE at a share price of ₹149.28 and on BSE with a share price of ₹148.6.
The market cap of Gujarat Kidney and Super is ₹1,176.97 Cr. as of Nov 20, 2026.
Gujarat Kidney and Super has never announced any dividend since the time of its listing on the BSE/NSE exchanges.
Gujarat Kidney and Super has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Gujarat Kidney and Super reported ₹38.68 Cr. in revenue, ₹5.84 Cr. in net profit, and ₹10.8 Cr. in EBITD as of Nov 04, 2026 for Q2 FY26-27.
There are no analyst predictions for stock price target for Gujarat Kidney and Super.
The PE ratio of Gujarat Kidney and Super is 61.92 as of Nov 20, 2026.
The PB ratio of Gujarat Kidney and Super is 4.56 as of Nov 20, 2026.
You can view the latest analyst reports on the Gujarat Kidney and Super reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.